<- Go home

Professional

[ANALYST] Jay Lee

Added to YB: 2024-10-04

Pitch date: 2024-10-03

GH [bullish]

Guardant Health, Inc.

+95.04%

current return

Author Info

No bio for this author

Company Info

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.

Market Cap

$5.9B

Pitch Price

$21.99

Price Target

47.00 (+16%)

Dividend

N/A

Sector

Health Care Providers and Services

Category

growth

Show full summary:
Guardant Health, Inc.: Strong Volume Growth; Guidance Revised Upward

GH: Liquid biopsy leader in genomic profiling, MRD testing, CRC screening. Guardant360 FDA-approved for CGP. Reveal MRD test launched 2021, Shield CRC screening LDT 2022. Targeting FDA approval 2024, USPSTF inclusion 2026. No moat, high uncertainty. FV $47. Cash flow positive by 2028. $4B revenue by 2032.

Read full article (8 min)